<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="7356825 doi: 10.3390/molecules25122796molecules-25-02796 : Review Antiviral Natural Products for Arbovirus" exact="Infections" post="GohVanessa Shi Li12https://orcid.org/0000-0002-9239-0223MokChee-Keng12*ChuJustin Jang Hann123*[1], micvgsl@nus.edu.sg[2], [3], *Correspondence: mokcheekeng@nus.edu.sg"/>
 <result pre="resulted in countless outbreaks globally. With a high proportion of" exact="infections" post="occurring in tropical and subtropical regions where arthropods tend"/>
 <result pre="that is heavily affected by arboviral diseases caused by dengue," exact="Japanese encephalitis," post="West Nile, Zika, and chikungunya viruses. Major gaps in"/>
 <result pre="diseases caused by dengue, Japanese encephalitis, West Nile, Zika, and" exact="chikungunya" post="viruses. Major gaps in protection against the most significant"/>
 <result pre="contributing to antiviral drug development and in reducing the global" exact="infection" post="burden of arboviruses. antiviral natural products arbovirus 1. Introduction"/>
 <result pre="have been identified, with approximately 150 arboviruses known to cause" exact="disease" post="in humans [1]. Most arboviruses causing human disease belong"/>
 <result pre="to cause disease in humans [1]. Most arboviruses causing human" exact="disease" post="belong to four families: Flaviviridae (genus Flavivirus), Togaviridae (genus"/>
 <result pre="Nairoviridae (genus Orthonairovirus), Orthomyxoviridae (genus Thogotovirus), Rhabdoviridae (genus Vesiculovirus), and" exact="Reoviridae" post="(genus Orbivirus) also contributing. Although arboviruses often cause large"/>
 <result pre="a flu-like illness. For this reason, the actual numbers of" exact="infection" post="cases may be under-reported or misdiagnosed as other illnesses."/>
 <result pre="of cases progress to the more severe forms of arboviral" exact="disease" post="that can be debilitating or potentially fatal, and usually"/>
 <result pre="facilitated the expansion of vectors into new territories to cause" exact="disease" post="[2,7,8]. With a high proportion of infections occurring in"/>
 <result pre="territories to cause disease [2,7,8]. With a high proportion of" exact="infections" post="occurring in tropical and subtropical regions where arthropods tend"/>
 <result pre="groups: flaviviruses and alphaviruses. These include the dengue virus (DENV)," exact="Japanese encephalitis" post="virus (JEV), West Nile virus (WNV), and Zika virus"/>
 <result pre="flaviviruses and alphaviruses. These include the dengue virus (DENV), Japanese" exact="encephalitis" post="virus (JEV), West Nile virus (WNV), and Zika virus"/>
 <result pre="virus (WNV), and Zika virus (ZIKV) which are flaviviruses, and" exact="chikungunya" post="virus (CHIKV) which is an alphavirus (refer to Table"/>
 <result pre="(CHIKV) which is an alphavirus (refer to Table 1) [10,11,12]." exact="Severe" post="clinical manifestations associated with each arbovirus mentioned herein have"/>
 <result pre="have been observed. For instance, hemorrhagic fever in DENV infections," exact="encephalitis" post="in JEV and WNV infections; severe myalgia and arthralgia"/>
 <result pre="JEV and WNV infections; severe myalgia and arthralgia in CHIKV" exact="infections" post="[1]. In the case of ZIKV infections, an increased"/>
 <result pre="In the case of ZIKV infections, an increased occurrence of" exact="congenital" post="microcephaly and Guillainâ€&quot;BarrÃ© syndrome was reported in ZIKV outbreak"/>
 <result pre="the case of ZIKV infections, an increased occurrence of congenital" exact="microcephaly" post="and Guillainâ€&quot;BarrÃ© syndrome was reported in ZIKV outbreak areas"/>
 <result pre="ZIKV infections, an increased occurrence of congenital microcephaly and Guillainâ€&quot;BarrÃ©" exact="syndrome" post="was reported in ZIKV outbreak areas [13,14]. Despite advances"/>
 <result pre="of potent and effective antivirals against arboviruses to reduce the" exact="infection" post="burden which impacts millions across the globe. A potential"/>
 <result pre="include DENV, JEV, WNV, ZIKV, and many others such as" exact="yellow fever" post="virus and hepatitis C virus (HCV). 2.1. Dengue Virus"/>
 <result pre="ZIKV, and many others such as yellow fever virus and" exact="hepatitis C" post="virus (HCV). 2.1. Dengue Virus (DENV) Transmitted by the"/>
 <result pre="as yellow fever virus and hepatitis C virus (HCV). 2.1." exact="Dengue" post="Virus (DENV) Transmitted by the Aedes aegypti and Aedes"/>
 <result pre="considered to be the most widespread arbovirus worldwide, with the" exact="disease" post="endemic in more than 100 countries [24]. Of the"/>
 <result pre="100 countries [24]. Of the 96 million cases of DENV" exact="infections" post="that occur annually, 70% of the disease burden is"/>
 <result pre="cases of DENV infections that occur annually, 70% of the" exact="disease" post="burden is contributed by Asia alone, followed by Latin"/>
 <result pre="of dengue cases could be under-reported [26]. Symptoms of dengue" exact="infection" post="include high fever (40 Â°C), severe headache, retro-orbital pain,"/>
 <result pre="include high fever (40 Â°C), severe headache, retro-orbital pain, and" exact="muscle" post="and joint pain. In rare cases, severe dengue may"/>
 <result pre="retro-orbital pain, and muscle and joint pain. In rare cases," exact="severe dengue" post="may occur with serious manifestationsâ€&quot;including capillary leakage, fluid accumulation"/>
 <result pre="[27]. Young children in particular are at greater risk of" exact="severe dengue" post="as they may be less able to compensate for"/>
 <result pre="safe and efficacious in people who previously had a DENV" exact="infection" post="(seropositive individuals); however, it confers a predisposition to severe"/>
 <result pre="DENV infection (seropositive individuals); however, it confers a predisposition to" exact="severe dengue" post="in those who experience their first natural dengue infection"/>
 <result pre="severe dengue in those who experience their first natural dengue" exact="infection" post="after vaccination (seronegative individuals) [27,29]. Therefore, it may not"/>
 <result pre="agent exists for dengue and treatment is mainly supportive. 2.2." exact="Japanese Encephalitis" post="Virus (JEV) JEV is the leading cause of viral"/>
 <result pre="exists for dengue and treatment is mainly supportive. 2.2. Japanese" exact="Encephalitis" post="Virus (JEV) JEV is the leading cause of viral"/>
 <result pre="Japanese Encephalitis Virus (JEV) JEV is the leading cause of" exact="viral encephalitis" post="in Asia with approximately 68,000 cases of infection estimated"/>
 <result pre="Encephalitis Virus (JEV) JEV is the leading cause of viral" exact="encephalitis" post="in Asia with approximately 68,000 cases of infection estimated"/>
 <result pre="of viral encephalitis in Asia with approximately 68,000 cases of" exact="infection" post="estimated to occur annually [30]. Culex spp. mosquitoes are"/>
 <result pre="mosquitoes, pigs and/or wading water birds; humans are incidental hosts." exact="Japanese encephalitis" post="is primarily a disease of children, with ~75% of"/>
 <result pre="pigs and/or wading water birds; humans are incidental hosts. Japanese" exact="encephalitis" post="is primarily a disease of children, with ~75% of"/>
 <result pre="birds; humans are incidental hosts. Japanese encephalitis is primarily a" exact="disease" post="of children, with ~75% of cases occurring in children"/>
 <result pre="that most adults in endemic regions have natural immunity after" exact="childhood" post="infection; however, individuals of any age may be affected"/>
 <result pre="age may be affected [30]. The vast majority of JEV" exact="infections" post="are asymptomatic or present as a flu-like illness. JEV"/>
 <result pre="JEV can effectively cross the bloodâ€&quot;brain barrier (BBB) to cause" exact="acute" post="encephalitis, with severe manifestations including high fever, headache, vomiting,"/>
 <result pre="urgent need for a safe and effective cure for JEV" exact="infection" post="and the development of a safer, single-dose vaccine is"/>
 <result pre="symptoms [40]. The majority of people with symptoms will develop" exact="West Nile fever," post="and only a small number will progress to severe"/>
 <result pre="a small number will progress to severe West Nile neuroinvasive" exact="disease" post="(WNND), which is potentially fatal (less than 1% of"/>
 <result pre="people) [41]. Serious manifestations of WNND include encephalitis, meningitis, and" exact="acute" post="flaccid paralysis [42]. Additionally, some patients suffer fatigue, muscle"/>
 <result pre="and acute flaccid paralysis [42]. Additionally, some patients suffer fatigue," exact="muscle" post="weakness, and persistent tremors, lasting weeks to years even"/>
 <result pre="first time in the Americas, with a massive outbreak of" exact="infections" post="occurring in Brazil [50,51]. Symptoms of ZIKV infection resembles"/>
 <result pre="outbreak of infections occurring in Brazil [50,51]. Symptoms of ZIKV" exact="infection" post="resembles that of dengue fever, which includes fever, headache,"/>
 <result pre="in Brazil [50,51]. Symptoms of ZIKV infection resembles that of" exact="dengue fever," post="which includes fever, headache, rashes, and joint and muscle"/>
 <result pre="dengue fever, which includes fever, headache, rashes, and joint and" exact="muscle" post="pain. Although infections are usually mild or asymptomatic, neurological"/>
 <result pre="includes fever, headache, rashes, and joint and muscle pain. Although" exact="infections" post="are usually mild or asymptomatic, neurological disorders have been"/>
 <result pre="have been associated with ZIKV infections. An increased occurrence of" exact="congenital" post="microcephaly resulting from abnormal brain development, as well as"/>
 <result pre="been associated with ZIKV infections. An increased occurrence of congenital" exact="microcephaly" post="resulting from abnormal brain development, as well as Guillainâ€&quot;BarrÃ©"/>
 <result pre="infections. An increased occurrence of congenital microcephaly resulting from abnormal" exact="brain" post="development, as well as Guillainâ€&quot;BarrÃ© syndrome (GBS) and acute"/>
 <result pre="microcephaly resulting from abnormal brain development, as well as Guillainâ€&quot;BarrÃ©" exact="syndrome" post="(GBS) and acute myelitis in adults were reported in"/>
 <result pre="abnormal brain development, as well as Guillainâ€&quot;BarrÃ© syndrome (GBS) and" exact="acute" post="myelitis in adults were reported in ZIKV outbreak areas"/>
 <result pre="brain development, as well as Guillainâ€&quot;BarrÃ© syndrome (GBS) and acute" exact="myelitis" post="in adults were reported in ZIKV outbreak areas [14,52,53,54,55]."/>
 <result pre="were reported in ZIKV outbreak areas [14,52,53,54,55]. Long-term consequences of" exact="microcephaly" post="can range from mild developmental delays to severe motor"/>
 <result pre="patients who suffer from GBS experience a rapid onset of" exact="muscle" post="weakness which may lead to incapability of walking, trouble"/>
 <result pre="which may lead to incapability of walking, trouble swallowing and" exact="facial paralysis" post="[13,14]. Although studies have shown that there is a"/>
 <result pre="maculopapular rash, back pain, myalgia, and polyarthralgia [57,63]. Complications of" exact="CHIKV infection" post="include respiratory failure and meningoencephalitis [13]. Some patients have"/>
 <result pre="rash, back pain, myalgia, and polyarthralgia [57,63]. Complications of CHIKV" exact="infection" post="include respiratory failure and meningoencephalitis [13]. Some patients have"/>
 <result pre="pain, myalgia, and polyarthralgia [57,63]. Complications of CHIKV infection include" exact="respiratory" post="failure and meningoencephalitis [13]. Some patients have been reported"/>
 <result pre="polyarthralgia [57,63]. Complications of CHIKV infection include respiratory failure and" exact="meningoencephalitis" post="[13]. Some patients have been reported to experience recurrent"/>
 <result pre="and meningoencephalitis [13]. Some patients have been reported to experience" exact="recurrent" post="and persistent myalgia and arthralgia which last for weeks"/>
 <result pre="there is currently no approved antiviral treatment or vaccine for" exact="CHIKV infection;" post="treatment is usually symptomatic [65]. To date, CHIKV has"/>
 <result pre="antiviral treatment or vaccine for CHIKV infection; treatment is usually" exact="symptomatic" post="[65]. To date, CHIKV has been detected in more"/>
 <result pre="However, its symptoms may be clinically indistinguishable from dengue and" exact="chikungunya" post="fever, hence leading to the misdiagnosis and underestimation of"/>
 <result pre="to the misdiagnosis and underestimation of the number of MAYV" exact="infection" post="cases [76,77]. Due to the potential of MAYV mimicking"/>
 <result pre="antiviral, anti-bacterial, antioxidant, anti-inflammatory, and anti-carcinogenic effects [84,85,86,87,88]. They are" exact="secondary" post="metabolites of plants that are involved in protecting the"/>
 <result pre="antiviral activities that can target various enzymes to disrupt the" exact="viral" post="replication cycle [20,23,92,93]. In addition, not all flavonoids are"/>
 <result pre="development against the target viruses. Strategies to overcome the poor" exact="systemic" post="bioavailability of compounds will be discussed later. Numerous flavonoids,"/>
 <result pre="widely used throughout the world, and in traditional Asian and" exact="African" post="medicine to treat a wide range of illnesses for"/>
 <result pre="antiviral activity against several enveloped viruses including PR8 influenza virus," exact="vaccinia" post="virus, pseudorabies virus, Newcastle disease virus [98], HCV [120],"/>
 <result pre="enveloped viruses including PR8 influenza virus, vaccinia virus, pseudorabies virus," exact="Newcastle disease" post="virus [98], HCV [120], and human immunodeficiency virus (HIV)"/>
 <result pre="viruses including PR8 influenza virus, vaccinia virus, pseudorabies virus, Newcastle" exact="disease" post="virus [98], HCV [120], and human immunodeficiency virus (HIV)"/>
 <result pre="pseudorabies virus, Newcastle disease virus [98], HCV [120], and human" exact="immunodeficiency" post="virus (HIV) [121]. In contrast, the non-enveloped enterovirus-A71 (EV-A71)"/>
 <result pre="shown to possess potent antiviral activity against HIV, influenza virus," exact="herpes" post="simplex virus (HSV), and HCV [92,101,122,123]. A direct virucidal"/>
 <result pre="EGCG exerts its antiviral effect at the early stages of" exact="viral" post="replication, possibly by binding directly to the viral particle"/>
 <result pre="stages of viral replication, possibly by binding directly to the" exact="viral" post="particle to inhibit host cell attachment [92,100,101]. Carneiro and"/>
 <result pre="it was established that EGCG could destroy and destabilize the" exact="viral" post="envelope phospholipids, thus leading to virus destruction [123]. Despite"/>
 <result pre="and spread to foetal tissues such as the brain, eyes," exact="and heart" post="[125]. Together, these studies show that EGCG is a"/>
 <result pre="spread to foetal tissues such as the brain, eyes, and" exact="heart" post="[125]. Together, these studies show that EGCG is a"/>
 <result pre="good liposolubility in an in vitro model using cultured rat" exact="brain" post="microvascular endothelial cells (BMECs) [127,128]. Recently, Lee and colleagues"/>
 <result pre="colleagues (2019) reported that pinocembrin is able to inhibit ZIKV" exact="infection" post="in human placental JEG-3 and human hepatoma Huh7 cell"/>
 <result pre="an important anti-malarial agent which has been used to treat" exact="malaria" post="from as early as the 1600s [130]. It was"/>
 <result pre="produces mild to severe side effects at therapeutic concentrations in" exact="malaria" post="treatment [130]. Mild symptoms include headache, nausea, and tinnitus;"/>
 <result pre="must be performed before it can be prescribed to treat" exact="viral" post="infections. 4.1.5. Other Potential Antiviral Compounds against Arboviruses Other"/>
 <result pre="traditional medicine among the local people for dysentery and common" exact="infectious diseases" post="[113]. Given the high content of polyphenols present in"/>
 <result pre="a study evaluated its ability to inhibit ZIKV and DENV" exact="infections" post="[113]. The data showed that P. mauritianum extract was"/>
 <result pre="toxicity and did not exert a genotoxic effect on human" exact="primary" post="cell lines tested [113]. However, more work needs to"/>
 <result pre="investigate its potential to be an anti-flaviviral agent. 4.2.2. Silymarin" exact="Complex" post="Silymarin is a complex extracted from milk thistle (Silybum"/>
 <result pre="hepatoprotective activities, it is used as a supportive treatment for" exact="chronic" post="liver diseases, hepatocellular carcinoma, and liver cirrhosis [134]. In"/>
 <result pre="is used as a supportive treatment for chronic liver diseases," exact="hepatocellular carcinoma," post="and liver cirrhosis [134]. In a two-year toxicity study"/>
 <result pre="a supportive treatment for chronic liver diseases, hepatocellular carcinoma, and" exact="liver cirrhosis" post="[134]. In a two-year toxicity study of silymarin conducted"/>
 <result pre="supportive treatment for chronic liver diseases, hepatocellular carcinoma, and liver" exact="cirrhosis" post="[134]. In a two-year toxicity study of silymarin conducted"/>
 <result pre="inhibit HCV both in vitro and in vivo by inhibiting" exact="viral" post="entry, RNA synthesis, and viral protein expression (refer to"/>
 <result pre="and in vivo by inhibiting viral entry, RNA synthesis, and" exact="viral" post="protein expression (refer to Table 3) [137]. In a"/>
 <result pre="MAYV replication and attenuating MAYV-induced oxidative stress caused by MAYV" exact="infection" post="[115]. This suggests that there could be potential in"/>
 <result pre="treatment can be made available to infected patients to accelerate" exact="viral" post="clearance and to reduce disease severity [138]. Other applications"/>
 <result pre="to infected patients to accelerate viral clearance and to reduce" exact="disease" post="severity [138]. Other applications for anti-arboviral drug development include"/>
 <result pre="outbreaks [138]. Many antiviral candidates have been found to inhibit" exact="viral" post="replication using in vitro approaches, and only a few"/>
 <result pre="the antiviral candidates in order to elucidate the host or" exact="viral" post="receptors involved in suppressing infection effectively, as well as"/>
 <result pre="to elucidate the host or viral receptors involved in suppressing" exact="infection" post="effectively, as well as to examine the possibility of"/>
 <result pre="in the intestine, poor water solubility, high metabolism rate, rapid" exact="systemic" post="elimination, and remains a challenge faced by many [97,101,108,114,137]."/>
 <result pre="withstand rapid degradation while retaining curcuminâ€™s antiviral activity against HIV-1" exact="infection" post="in cultured lymphoblastoid T cells and peripheral blood mononuclear"/>
 <result pre="activity against HIV-1 infection in cultured lymphoblastoid T cells and" exact="peripheral" post="blood mononuclear cells [145]. It was demonstrated to have"/>
 <result pre="also offer flexibility of use in other treatments including cancer," exact="cardiovascular" post="diseases, neurodegenerative diseases, and diabetes [91,126,146]. With an abundance"/>
 <result pre="in other treatments including cancer, cardiovascular diseases, neurodegenerative diseases, and" exact="diabetes" post="[91,126,146]. With an abundance of natural products to screen"/>
 <result pre="in contributing to antiviral drug development, and in reducing the" exact="infection" post="burden that impacts millions globally. Acknowledgments We acknowledge support"/>
 <result pre="studies that have been reported. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="no conflict of interest. References References 1.YoungP.R.NgL.F.P.HallR.A.SmithD.W.JohansenC.A.Chapter 14-Arbovirus InfectionsMansonâ€™s Tropical" exact="Infectious" post="Diseases23rd ed.FarrarJ.HotezP.J.JunghanssT.KangG.LallooD.WhiteN.J.W.B. SaundersLondon, UK2014129161 2.Wilder-SmithA.OoiE.-E.HorstickO.WillsB.DengueLancet201939335036310.1016/S0140-6736(18)32560-130696575 3.YoungP.R.Arboviruses: A Family on"/>
 <result pre="research and public healthLancet Infect. Dis.201717e101e10610.1016/S1473-3099(16)30518-728011234 5.MarchiS.TrombettaC.M.MontomoliE.Emerging and Re-emerging Arboviral" exact="Diseases" post="as a Global Health ProblemPublic Health-Emerging and Re-emerging IssuesMajumderM.A.A.RusselK.SayeedaR.InTechLondon,"/>
 <result pre="and future arboviral threatsAntivir. Res.20108532834510.1016/j.antiviral.2009.10.00819857523 9.collab: World Health OrganizationFact Sheet:" exact="Dengue" post="and Severe DengueAvailable online: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue(accessed on 1 April 2020)"/>
 <result pre="arboviral threatsAntivir. Res.20108532834510.1016/j.antiviral.2009.10.00819857523 9.collab: World Health OrganizationFact Sheet: Dengue and" exact="Severe" post="DengueAvailable online: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue(accessed on 1 April 2020) 10.GouldE.PetterssonJ.HiggsS.CharrelR.De LamballerieX.Emerging"/>
 <result pre="and Zika DiseaseChikungunya and Zika VirusesHiggsS.VanlandinghamD.L.PowersA.M.Academic PressLondon, UK2018698510.1016/B978-0-12-811865-8.00003-9 14.Cao-LormeauV.-M.BlakeA.MonsS.LastÃ¨reS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-BarrÃ©" exact="Syndrome" post="outbreak associated with Zika virus infection in French Polynesia:"/>
 <result pre="VirusesHiggsS.VanlandinghamD.L.PowersA.M.Academic PressLondon, UK2018698510.1016/B978-0-12-811865-8.00003-9 14.Cao-LormeauV.-M.BlakeA.MonsS.LastÃ¨reS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-BarrÃ© Syndrome outbreak associated with Zika" exact="virus infection" post="in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 15.collab: Sanofi PasteurPress"/>
 <result pre="PressLondon, UK2018698510.1016/B978-0-12-811865-8.00003-9 14.Cao-LormeauV.-M.BlakeA.MonsS.LastÃ¨reS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-BarrÃ© Syndrome outbreak associated with Zika virus" exact="infection" post="in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 15.collab: Sanofi PasteurPress"/>
 <result pre="A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 15.collab: Sanofi PasteurPress Release: DengvaxiaÂ®, Worldâ€™s First" exact="Dengue" post="Vaccine, Approved in MexicoAvailable online: https://www.sanofi.com/en/media-room/press-releases/2015/2015-12-09-16-30-00(accessed on 9 April"/>
 <result pre="online: https://www.sanofi.com/en/media-room/press-releases/2015/2015-12-09-16-30-00(accessed on 9 April 2020) 16.collab: World Health OrganizationJapanese" exact="Encephalitis" post="Vaccines: WHO position paperâ€&quot;February 2015Wkly Epidemiol. Rec.201590698825726573 17.NgT.HathawayD.JenningsN.ChampD.ChiangY.W.ChuH.J.Equine vaccine"/>
 <result pre="virus vaccine, live Flavivirus chimera, in horses with a clinical" exact="disease" post="challenge modelEquine Vet. J.20073949149710.2746/042516407X21741618065305 19.collab: U.S. Food and Drug"/>
 <result pre="of Flavonoids: An OverviewSci. World J.2013201316275010.1155/2013/16275024470791 21.SuroowanS.MahomoodallyF.RagooL.Management and Treatment of" exact="Dengue" post="and Chikungunya-Natural Products to the RescueComb. Chem. High Throughput"/>
 <result pre="Screen.20161955456410.2174/138620731966616050612340127151484 22.RodriguezA.K.MunozA.L.SeguraN.A.RangelH.R.BelloF.Molecular characteristics and replication mechanism of dengue, zika and" exact="chikungunya" post="arboviruses, and their treatments with natural extracts from plants:"/>
 <result pre="reviewEXCLI J.201918988100610.17179/excli2019-182531762724 23.OliveiraA.F.TeixeiraR.R.OliveiraA.S.SouzaA.P.SilvaM.L.PaulaS.O.Potential Antivirals: Natural Products Targeting Replication Enzymes of" exact="Dengue" post="and Chikungunya VirusesMolecules20172250510.3390/molecules22030505 24.BradyO.J.GethingP.W.BhattS.MessinaJ.P.BrownsteinJ.S.HoenA.G.MoyesC.L.FarlowA.W.ScottT.W.HayS.I.Refining the global spatial limits of"/>
 <result pre="in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and" exact="Dengue" post="VirusClin. Infect. Dis.2016631584159010.1093/cid/ciw58927578819 27.SridharS.LuedtkeA.LangevinE.ZhuM.BonaparteM.MachabertT.SavarinoS.ZambranoB.MoureauA.KhromavaA.et al.Effect of Dengue Serostatus on"/>
 <result pre="Chikungunya Virus, and Dengue VirusClin. Infect. Dis.2016631584159010.1093/cid/ciw58927578819 27.SridharS.LuedtkeA.LangevinE.ZhuM.BonaparteM.MachabertT.SavarinoS.ZambranoB.MoureauA.KhromavaA.et al.Effect of" exact="Dengue" post="Serostatus on Dengue Vaccine Safety and EfficacyN. Engl. J."/>
 <result pre="Dengue VirusClin. Infect. Dis.2016631584159010.1093/cid/ciw58927578819 27.SridharS.LuedtkeA.LangevinE.ZhuM.BonaparteM.MachabertT.SavarinoS.ZambranoB.MoureauA.KhromavaA.et al.Effect of Dengue Serostatus on" exact="Dengue" post="Vaccine Safety and EfficacyN. Engl. J. Med.201837932734010.1056/NEJMoa180082029897841 28.collab: Sanofi"/>
 <result pre="J. Med.201837932734010.1056/NEJMoa180082029897841 28.collab: Sanofi PasteurPress Release: Sanofi Updates Information on" exact="Dengue" post="VaccineAvailable online: https://www.sanofi.com/en/media-room/press-releases/2017/2017-11-29-17-36-30(accessed on 9 April 2020) 29.HadinegoroS.R.Arredondo-GarcÃ­aJ.L.CapedingM.R.DesedaC.ChotpitayasunondhT.DietzeR.Hj Muhammad"/>
 <result pre="2020) 29.HadinegoroS.R.Arredondo-GarcÃ­aJ.L.CapedingM.R.DesedaC.ChotpitayasunondhT.DietzeR.Hj Muhammad IsmailH.I.ReynalesH.LimkittikulK.Rivera-MedinaD.M.et al.Efficacy and Long-Term Safety of a" exact="Dengue" post="Vaccine in Regions of Endemic DiseaseN. Engl. J. Med.20153731195120610.1056/NEJMoa150622326214039"/>
 <result pre="33.SolomonT.Japanese encephalitisJ. Neurol. Neurosurg. Psychiatry20006840541510.1136/jnnp.68.4.40510727474 34.Van GesselY.KladeC.S.PutnakR.FormicaA.KrasaesubS.SpruthM.CenaB.TungtaengA.GettayacaminM.DewasthalyS.Correlation of protection against" exact="Japanese encephalitis" post="virus and JE vaccine (IXIAROÂ®) induced neutralizing antibody titersVaccine2011295925593110.1016/j.vaccine.2011.06.06221723353"/>
 <result pre="encephalitisJ. Neurol. Neurosurg. Psychiatry20006840541510.1136/jnnp.68.4.40510727474 34.Van GesselY.KladeC.S.PutnakR.FormicaA.KrasaesubS.SpruthM.CenaB.TungtaengA.GettayacaminM.DewasthalyS.Correlation of protection against Japanese" exact="encephalitis" post="virus and JE vaccine (IXIAROÂ®) induced neutralizing antibody titersVaccine2011295925593110.1016/j.vaccine.2011.06.06221723353"/>
 <result pre="encephalitisHum. Vaccines Immunother.20141026327910.4161/hv.26902 37.NashD.MostashariF.FineA.MillerJ.Oâ€™LearyD.MurrayK.HuangA.RosenbergA.GreenbergA.ShermanM.et al.The Outbreak of West Nile Virus" exact="Infection" post="in the New York City Area in 1999N. Engl."/>
 <result pre="manifestations of West Nile virus diseaseEmerg. Infect. Dis.2005111174117910.3201/eid1108.050289b16102303 41.MostashariF.BunningM.L.KitsutaniP.T.SingerD.A.NashD.CooperM.J.KatzN.LiljebjelkeK.A.BiggerstaffB.J.FineA.D.et al.Epidemic" exact="West Nile encephalitis," post="New York, 1999: Results of a household-based seroepidemiological surveyLancet200135826126410.1016/S0140-6736(01)05480-011498211"/>
 <result pre="Polynesia, South Pacific, 2013Emerg. Infect. Dis.2014201084108610.3201/eid2006.14013824856001 49.Dupont-RouzeyrolM.Oâ€™ConnorO.CalvezE.DaurÃ¨sM.JohnM.GrangeonJ.-P.GourinatA.-C.Co-infection with Zika and" exact="Dengue" post="Viruses in 2 Patients, New Caledonia, 2014Emerg. Infect. Dis.20152138138210.3201/eid2102.14155325625687"/>
 <result pre="J. Med.201637495195810.1056/NEJMoa160065126862926 53.Schuler-FacciniL.RibeiroE.M.FeitosaI.M.L.HorovitzD.D.G.CavalcantiD.P.PessoaA.DoriquIM.J.R.NeriJ.I.de Pina NetoJ.M.WanderleyH.Y.C.et al.Possible Association Between Zika Virus" exact="Infection" post="and Microcephalyâ€&quot;Brazil, 2015Morb. Mortal. Wkly Rep.201665596210.15585/mmwr.mm6503e226820244 54.MÃ©charlesS.M.D.HerrmannC.M.D.PoullainP.M.D.TranT.-H.M.B.DeschampsN.M.B.MathonG.M.D.LandaisA.M.D.BreurecS.M.D.LannuzelA.P.Acute myelitis due"/>
 <result pre="Zika Virus Infection and Microcephalyâ€&quot;Brazil, 2015Morb. Mortal. Wkly Rep.201665596210.15585/mmwr.mm6503e226820244 54.MÃ©charlesS.M.D.HerrmannC.M.D.PoullainP.M.D.TranT.-H.M.B.DeschampsN.M.B.MathonG.M.D.LandaisA.M.D.BreurecS.M.D.LannuzelA.P.Acute" exact="myelitis" post="due to Zika virus infectionLancet2016387148110.1016/S0140-6736(16)00644-926946926 55.CarteauxG.MaquartM.BedetA.ContouD.BrugiÃ¨resP.FouratiS.de LangavantL.C.de BrouckerT.Brun-BuissonC.Leparc-GoffartI.et al.Zika"/>
 <result pre="DiscoveriesChikungunya and Zika VirusesHiggsS.VanlandinghamD.L.PowersA.M.Academic PressLondon, UK201811310.1016/b978-0-12-811865-8.00001-5 57.RobinsonM.C.An epidemic of virus" exact="disease" post="in Southern Province, Tanganyika territory, in 1952â€&quot;1953Trans. R. Soc."/>
 <result pre="Hyg.195549283210.1016/0035-9203(55)90080-814373834 58.CagliotiC.LalleE.CastillettiC.CarlettiF.CapobianchiM.R.BordiL.Chikungunya virus infection: An overviewNew Microbiol.20133621123912863 59.HammonW.M.RudnickA.SatherG.E.Viruses Associated with" exact="Epidemic" post="Hemorrhagic Fevers of the Philippines and ThailandScience19601311102110310.1126/science.131.3407.110214399343 60.WeaverS.C.Arrival of"/>
 <result pre="58.CagliotiC.LalleE.CastillettiC.CarlettiF.CapobianchiM.R.BordiL.Chikungunya virus infection: An overviewNew Microbiol.20133621123912863 59.HammonW.M.RudnickA.SatherG.E.Viruses Associated with Epidemic" exact="Hemorrhagic" post="Fevers of the Philippines and ThailandScience19601311102110310.1126/science.131.3407.110214399343 60.WeaverS.C.Arrival of Chikungunya"/>
 <result pre="virus infection: An overviewNew Microbiol.20133621123912863 59.HammonW.M.RudnickA.SatherG.E.Viruses Associated with Epidemic Hemorrhagic" exact="Fevers" post="of the Philippines and ThailandScience19601311102110310.1126/science.131.3407.110214399343 60.WeaverS.C.Arrival of Chikungunya Virus"/>
 <result pre="in the New WorldWest. J. Emerg. Med.20161767167910.5811/westjem.2016.9.3090427833670 65.WongK.Z.ChuJ.J.H.The Interplay of" exact="Viral" post="and Host Factors in Chikungunya Virus Infection: Targets for"/>
 <result pre="evidence from Sri Lanka and SingaporeJ. Gen. Virol.2010911067107610.1099/vir.0.015743-019955565 68.HochedezP.HausfaterP.JaureguiberryS.GayF.DatryA.DanisM.BricaireF.BossiP.Cases of" exact="chikungunya" post="fever imported from the islands of the South West"/>
 <result pre="US Travelers Returning from India, 2006Emerg. Infect. Dis.20071376476710.3201/eid1305.07001517553261 71.AzevedoR.S.S.SilvaE.V.P.CarvalhoV.L.RodriguesS.G.Nunes NetoJ.P.MonteiroH.A.O.PeixotoV.S.ChiangJ.O.NunesM.R.T.VasconcelosP.F.C.Mayaro" exact="Fever" post="Virus, Brazilian AmazonEmerg. Infect. Dis.200915183010.3201/eid1511.09046119891877 72.AugusteA.J.LiriaJ.ForresterN.L.GiambalvoD.MoncadaM.LongK.C.MorÃ³nD.de ManzioneN.TeshR.B.HalseyE.S.et al.Evolutionary and"/>
 <result pre="Returning from India, 2006Emerg. Infect. Dis.20071376476710.3201/eid1305.07001517553261 71.AzevedoR.S.S.SilvaE.V.P.CarvalhoV.L.RodriguesS.G.Nunes NetoJ.P.MonteiroH.A.O.PeixotoV.S.ChiangJ.O.NunesM.R.T.VasconcelosP.F.C.Mayaro Fever Virus," exact="Brazilian" post="AmazonEmerg. Infect. Dis.200915183010.3201/eid1511.09046119891877 72.AugusteA.J.LiriaJ.ForresterN.L.GiambalvoD.MoncadaM.LongK.C.MorÃ³nD.de ManzioneN.TeshR.B.HalseyE.S.et al.Evolutionary and Ecological Characterization"/>
 <result pre="72.AugusteA.J.LiriaJ.ForresterN.L.GiambalvoD.MoncadaM.LongK.C.MorÃ³nD.de ManzioneN.TeshR.B.HalseyE.S.et al.Evolutionary and Ecological Characterization of Mayaro Virus Strains" exact="Isolated" post="during an Outbreak, Venezuela, 2010Emerg. Infect. Dis.2015211742175010.3201/eid2110.14166026401714 73.ZuchiN.HeinenL.B.D.S.SantosM.A.M.D.PereiraF.C.SlhessarenkoR.D.Molecular detection"/>
 <result pre="arbovirus of the AmericasFuture Virol.2015101109112210.2217/fvl.15.76 77.VieiraC.J.d.S.P.SilvaD.J.F.d.BarretoE.S.SiqueiraC.E.H.ColomboT.E.OzanicK.SchmidtD.J.DrumondB.P.MondiniA.NogueiraM.L.et al.Detection of Mayaro virus" exact="infections" post="during a dengue outbreak in Mato Grosso, BrazilActa Trop.2015147121610.1016/j.actatropica.2015.03.02025817238"/>
 <result pre="SantosC.N.D.et al.Extract from Aphloia theiformis, an edible indigenous plant from" exact="Reunion Island," post="impairs Zika virus attachment to the host cell surfaceSci."/>
 <result pre="activityParasites Vectors2014713010.1186/1756-3305-7-13024678592 83.JohariJ.KianmehrA.MustafaM.AbubakarS.ZandiK.Antiviral Activity of Baicalein and Quercetin against the" exact="Japanese Encephalitis" post="VirusInt. J. Mol. Sci.201213167851679510.3390/ijms13121678523222683 84.PancheA.N.DiwanA.D.ChandraS.R.Flavonoids: An overviewJ. Nutr. Sci.2016510.1017/jns.2016.41"/>
 <result pre="Vectors2014713010.1186/1756-3305-7-13024678592 83.JohariJ.KianmehrA.MustafaM.AbubakarS.ZandiK.Antiviral Activity of Baicalein and Quercetin against the Japanese" exact="Encephalitis" post="VirusInt. J. Mol. Sci.201213167851679510.3390/ijms13121678523222683 84.PancheA.N.DiwanA.D.ChandraS.R.Flavonoids: An overviewJ. Nutr. Sci.2016510.1017/jns.2016.41"/>
 <result pre="Gallate against the Flaviviruses West Nile Virus, Zika Virus, and" exact="Dengue" post="VirusFront. Microbiol.2017810.3389/fmicb.2017.01314 93.ColpittsC.C.SchangL.M.A Small Molecule Inhibits Virion Attachment to"/>
 <result pre="enveloped viruses infectivity by curcuminPLoS ONE20138e6248210.1371/journal.pone.006248223658730 99.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and" exact="chikungunya" post="virus infection by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 100.WeberC.SlivaK.Von RheinC.KÃ¼mmererB.M.SchnierleB.S.The"/>
 <result pre="viruses infectivity by curcuminPLoS ONE20138e6248210.1371/journal.pone.006248223658730 99.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and chikungunya" exact="virus infection" post="by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 100.WeberC.SlivaK.Von RheinC.KÃ¼mmererB.M.SchnierleB.S.The green tea"/>
 <result pre="infectivity by curcuminPLoS ONE20138e6248210.1371/journal.pone.006248223658730 99.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and chikungunya virus" exact="infection" post="by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 100.WeberC.SlivaK.Von RheinC.KÃ¼mmererB.M.SchnierleB.S.The green tea"/>
 <result pre="bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 100.WeberC.SlivaK.Von RheinC.KÃ¼mmererB.M.SchnierleB.S.The green tea catechin, epigallocatechin gallate inhibits" exact="chikungunya" post="virus infectionAntivir. Res.20151131310.1016/j.antiviral.2014.11.00125446334 101.CarneiroB.M.BatistaM.N.BragaA.C.S.NogueiraM.L.RahalP.The green tea molecule EGCG inhibits"/>
 <result pre="Chikungunya Virus Replication by Harringtonine, a Novel Antiviral That Suppresses" exact="Viral" post="Protein ExpressionAntimicrob. Agents Chemother.20135715516710.1128/AAC.01467-1223275491 103.FangC.-Y.ChenS.-J.WuH.-N.PingY.-H.LinC.-Y.ShiuanD.ChenC.-L.LeeY.-R.HuangK.-J.Honokiol, a Lignan Biphenol Derived"/>
 <result pre="Virus Replication by Harringtonine, a Novel Antiviral That Suppresses Viral" exact="Protein" post="ExpressionAntimicrob. Agents Chemother.20135715516710.1128/AAC.01467-1223275491 103.FangC.-Y.ChenS.-J.WuH.-N.PingY.-H.LinC.-Y.ShiuanD.ChenC.-L.LeeY.-R.HuangK.-J.Honokiol, a Lignan Biphenol Derived from"/>
 <result pre="103.FangC.-Y.ChenS.-J.WuH.-N.PingY.-H.LinC.-Y.ShiuanD.ChenC.-L.LeeY.-R.HuangK.-J.Honokiol, a Lignan Biphenol Derived from the Magnolia Tree, Inhibits" exact="Dengue" post="Virus Type 2 InfectionViruses201574894491010.3390/v709285226378567 104.GaudryA.BosS.ViranaickenW.RocheM.Krejbich-TrototP.GadeaG.DesprÃ¨sP.El-KalamouniC.The Flavonoid Isoquercitrin Precludes Initiation"/>
 <result pre="Lignan Biphenol Derived from the Magnolia Tree, Inhibits Dengue Virus" exact="Type 2" post="InfectionViruses201574894491010.3390/v709285226378567 104.GaudryA.BosS.ViranaickenW.RocheM.Krejbich-TrototP.GadeaG.DesprÃ¨sP.El-KalamouniC.The Flavonoid Isoquercitrin Precludes Initiation of Zika Virus"/>
 <result pre="2 InfectionViruses201574894491010.3390/v709285226378567 104.GaudryA.BosS.ViranaickenW.RocheM.Krejbich-TrototP.GadeaG.DesprÃ¨sP.El-KalamouniC.The Flavonoid Isoquercitrin Precludes Initiation of Zika Virus" exact="Infection" post="in Human CellsInt. J. Mol. Sci.201819109310.3390/ijms19041093 105.ZhangT.WuZ.DuJ.HuY.LiuL.YangF.JinQ.Anti-Japanese-Encephalitis-Viral Effects of"/>
 <result pre="Polyphenol-Rich Extract from Psiloxylon mauritianum, an Endemic Medicinal Plant from" exact="Reunion Island," post="Inhibits the Early Stages of Dengue and Zika Virus"/>
 <result pre="Medicinal Plant from Reunion Island, Inhibits the Early Stages of" exact="Dengue" post="and Zika Virus InfectionInt. J. Mol. Sci.201920186010.3390/ijms20081860 114.LaniR.HassandarvishP.ChiamC.W.MoghaddamE.ChuJ.J.H.RausaluK.MeritsA.HiggsS.VanlandinghamD.Abu BakarS.et"/>
 <result pre="J. Mol. Sci.201920186010.3390/ijms20081860 114.LaniR.HassandarvishP.ChiamC.W.MoghaddamE.ChuJ.J.H.RausaluK.MeritsA.HiggsS.VanlandinghamD.Abu BakarS.et al.Antiviral activity of silymarin against" exact="chikungunya" post="virusSci. Rep.201551142110.1038/srep1142126078201 115.CaminiF.C.da SilvaT.F.da Silva CaetanoC.C.AlmeidaL.T.FerrazA.C.Alves VitoretiV.M.de Mello SilvaB.de"/>
 <result pre="Signal.20081051154610.1089/ars.2007.176918370854 119.SharmaR.A.Phase I Clinical Trial of Oral Curcumin: Biomarkers of" exact="Systemic" post="Activity and ComplianceClin. Cancer Res.2004106847685410.1158/1078-0432.CCR-04-074415501961 120.ColpittsC.C.SchangL.M.RachmawatiH.FrentzenA.PfaenderS.BehrendtP.BrownR.J.P.BankwitzD.SteinmannJ.OttM.et al.Turmeric curcumin inhibits"/>
 <result pre="Trial of Oral Curcumin: Biomarkers of Systemic Activity and ComplianceClin." exact="Cancer" post="Res.2004106847685410.1158/1078-0432.CCR-04-074415501961 120.ColpittsC.C.SchangL.M.RachmawatiH.FrentzenA.PfaenderS.BehrendtP.BrownR.J.P.BankwitzD.SteinmannJ.OttM.et al.Turmeric curcumin inhibits entry of all hepatitis"/>
 <result pre="ComplianceClin. Cancer Res.2004106847685410.1158/1078-0432.CCR-04-074415501961 120.ColpittsC.C.SchangL.M.RachmawatiH.FrentzenA.PfaenderS.BehrendtP.BrownR.J.P.BankwitzD.SteinmannJ.OttM.et al.Turmeric curcumin inhibits entry of all" exact="hepatitis C" post="virus genotypes into human liver cellsGut2014631137114910.1136/gutjnl-2012-30429923903236 121.MazumderA.RaghavanK.WeinsteinJ.KohnK.W.PommierY.Inhibition of human"/>
 <result pre="C virus genotypes into human liver cellsGut2014631137114910.1136/gutjnl-2012-30429923903236 121.MazumderA.RaghavanK.WeinsteinJ.KohnK.W.PommierY.Inhibition of human" exact="immunodeficiency" post="virus type-1 integrase by curcuminBiochem. Pharmacol.1995491165117010.1016/0006-2952(95)98514-A7748198 122.CallandN.AlbeckaA.BelouzardS.WychowskiC.DuverlieG.DescampsV.HoberD.DubuissonJ.RouillÃ©Y.SÃ©ronK.(âˆ’)-Epigallocatechin-3-gallate is a"/>
 <result pre="integrase by curcuminBiochem. Pharmacol.1995491165117010.1016/0006-2952(95)98514-A7748198 122.CallandN.AlbeckaA.BelouzardS.WychowskiC.DuverlieG.DescampsV.HoberD.DubuissonJ.RouillÃ©Y.SÃ©ronK.(âˆ’)-Epigallocatechin-3-gallate is a new inhibitor of" exact="hepatitis C" post="virus entryHepatology20125572072910.1002/hep.2480322105803 123.YamaguchiK.HondaM.IkigaiH.HaraY.ShimamuraT.Inhibitory effects of (âˆ’)-epigallocatechin gallate on the"/>
 <result pre="effects of (âˆ’)-epigallocatechin gallate on the life cycle of human" exact="immunodeficiency" post="virus type 1 (HIV-1)Antivir. Res.200253193410.1016/S0166-3542(01)00189-911684313 124.WeisburgJ.H.WeissmanD.B.SedaghatT.BabichH.In Vitro Cytotoxicity of"/>
 <result pre="(âˆ’)-epigallocatechin gallate on the life cycle of human immunodeficiency virus" exact="type 1" post="(HIV-1)Antivir. Res.200253193410.1016/S0166-3542(01)00189-911684313 124.WeisburgJ.H.WeissmanD.B.SedaghatT.BabichH.In Vitro Cytotoxicity of Epigallocatechin Gallate and"/>
 <result pre="Cytotoxicity of Epigallocatechin Gallate and Tea Extracts to Cancerous and" exact="Normal" post="Cells from the Human Oral CavityBasic Clin. Pharmacol. Toxicol.20049519120010.1111/j.1742-7843.2004.pto_950407.x15504155"/>
 <result pre="new uses for existing drugsNat. Rev. Drug Discov.2004367368310.1038/nrd146815286734 134.FedericoA.DallioM.LoguercioC.Silymarin/Silybin and" exact="Chronic" post="Liver Disease: A Marriage of Many YearsMolecules20172219110.3390/molecules22020191 135.DunnickJ.K.SinghB.NyskaA.PeckhamJ.KisslingG.E.SandersJ.M.Investigating the"/>
 <result pre="SilymarinComplement. Med. Res.20081592010.1159/00011364818334810 137.WagonerJ.NegashA.KaneO.J.MartinezL.E.NahmiasY.BourneN.OwenD.M.GroveJ.BrimacombeC.McKeatingJ.A.et al.Multiple effects of silymarin on the" exact="hepatitis C" post="virus lifecycleHepatology2010511912192110.1002/hep.2358720512985 138.Wilder-SmithA.VanniceK.DurbinA.HombachJ.ThomasS.J.IraniT.SimmonsC.P.Zika vaccines and therapeutics: Landscape analysis and"/>
 <result pre="143.MinnelliC.LaudadioE.GaleazziR.BaruccaG.NotarstefanoV.CantariniM.ArmeniT.MobbiliG.Encapsulation of a Neutral Molecule into a Cationic Clay Material:" exact="Structural" post="Insight and Cytotoxicity of Resveratrol/Layered Double Hydroxide/BSA NanocompositesNanomaterials2019103310.3390/nano10010033 144.MinnelliC.GaleazziR.LaudadioE.AmiciA.RuscianoD.ArmeniT.CantariniM.StipaP.MobbiliG.Monoalkylated"/>
 <result pre="encephalitis. No Yes [16] WNV Flaviviridae(genus Flavivirus) Culex spp. Fever," exact="muscle" post="weakness, encephalitis, meningitis. No Not for humans. Vaccines for"/>
 <result pre="Baicalein Roots of Scutellaria baicalensis and Scutellaria lateriflora CHIKV -Inhibits" exact="viral" post="attachment to host cells -Has potent virucidal activity against"/>
 <result pre="attachment to host cells -Has potent virucidal activity against extracellular" exact="viral" post="particles -Time-of-addition assay, inactivation assay [95] JEV -Possibly inhibits"/>
 <result pre="virus entry to cells -Has potent virucidal activity against extracellular" exact="viral" post="particles -Foci forming unit reduction assay, qRT-PCR [83] 2"/>
 <result pre="curcumin -Possibly inhibits virus by targeting host pathway essential for" exact="viral" post="replication -Plaque assay [97] -Virucidal activity on enveloped viruses"/>
 <result pre="activity on enveloped viruses -Plaque reduction assay [98] CHIKV -Inhibits" exact="viral" post="attachment to host cells -Time-of-addition assay [99] ZIKVJEV -Inhibits"/>
 <result pre="viral attachment to host cells -Time-of-addition assay [99] ZIKVJEV -Inhibits" exact="viral" post="attachment to host cells -Time-of-addition assay [99] -Virucidal activity"/>
 <result pre="activity observed -Plaque assay [92] WNV -Affects early stages of" exact="viral" post="replication cycle -Virucidal activity observed -Plaque assay [92] ZIKV"/>
 <result pre="transduced HEK 293T cells [100] WNV -Affects early stages of" exact="viral" post="replication cycle -Virucidal activity observed -Plaque assay [92] ZIKV"/>
 <result pre="in various flowers and fruits CHIKV -Inhibits early stages of" exact="viral" post="replication -Time-of-addition assay [95] 7 Harringtonine Cephalotaxus harringtonia (Japanese"/>
 <result pre="Harringtonine Cephalotaxus harringtonia (Japanese plum yew) CHIKV -Possibly by inhibiting" exact="viral" post="protein synthesis -Time-of-addition assay, qRT-PCR, SDS-PAGE, western blot [102]"/>
 <result pre="Honokiol Bark or seed cones of Magnolia tree DEN-2 -Inhibits" exact="viral" post="entry to the host cells and suppresses in vitro"/>
 <result pre="viral entry to the host cells and suppresses in vitro" exact="viral" post="replication -Pre-treatment assay, viral yield reduction, and fluorescence focus"/>
 <result pre="host cells and suppresses in vitro viral replication -Pre-treatment assay," exact="viral" post="yield reduction, and fluorescence focus formation assay [103] 9"/>
 <result pre="squamosa (sugar apple) and Camellia sinensis (green tea) ZIKV -Inhibits" exact="viral" post="entry to the host cell -Time-of-addition assay [104] 10"/>
 <result pre="Honey, tea and red wine ZIKV -Inhibits post-entry processes of" exact="viral" post="life cycle -Inhibits viral RNA production and envelope protein"/>
 <result pre="wine ZIKV -Inhibits post-entry processes of viral life cycle -Inhibits" exact="viral" post="RNA production and envelope protein synthesis -Time-of-addition and time-of-removal"/>
 <result pre="longifolia leaves, tea, apple, onion and tomato DEN-2 -Inhibits intracellular" exact="viral" post="replication but not viral attachment and entry processes -Foci"/>
 <result pre="onion and tomato DEN-2 -Inhibits intracellular viral replication but not" exact="viral" post="attachment and entry processes -Foci forming unit reduction assay,"/>
 <result pre="assay [82] 14 Quercetagetin Leaves of Eriocaulon species. CHIKV -Inhibits" exact="viral" post="attachment to host cells -Has potent neutralizing effect against"/>
 <result pre="assay [95] 15 Quinine Cinchona tree DEN-1 to -4 -Inhibits" exact="viral" post="replication by reducing DENV RNA and viral protein synthesis"/>
 <result pre="to -4 -Inhibits viral replication by reducing DENV RNA and" exact="viral" post="protein synthesis -Virus internalization assay, focus-forming unit (FFU) assay"/>
 <result pre="western blot [109] 16 Resveratrol Grapes and peanuts ZIKV -Inhibits" exact="viral" post="attachment to host cells -Virucidal activity observed -Pre-treatment and"/>
 <result pre="from flavonoid-derivative library DEN-1 to -4 -Affects synthesis of both" exact="viral" post="protein and RNA -Pre-treatment, time-of-addition, and time-of-removal assays, qRT-PCR"/>
 <result pre="1 Aphloia theiformis extract^ Aphloia theiformis DEN-1 to -4 -Inhibits" exact="viral" post="attachment to host cells -Foci-forming immunodetection assay, virus inactivation"/>
 <result pre="cells -Foci-forming immunodetection assay, virus inactivation assay [81] ZIKV -Inhibits" exact="viral" post="attachment to host cells 2 Mushroom extracts^ L. rhinocerotis,"/>
 <result pre="rhinocerotis, P. giganteus, H. erinaceus and S. commune DEN-2 -Inhibits" exact="viral" post="attachment and entry to host cells -Time-of-addition studies, plaque"/>
 <result pre="extract^ Aerial parts of Psiloxylon mauritianum DEN-1 to -4 -Inhibits" exact="viral" post="attachment to host cells -Time-of-addition assay [113] ZIKV -Inhibits"/>
 <result pre="viral attachment to host cells -Time-of-addition assay [113] ZIKV -Inhibits" exact="viral" post="attachment to host cells 4 Silymarin complex (Silybin) Seeds"/>
 <result pre="CHIKV -In vitro antiviral activity observed -Inhibits post-entry stages of" exact="viral" post="replication cycle -Time-of-addition and time-of-removal studies, qRT-PCR and western"/>
</results>
